美股异动丨莫德纳盘前续涨5.6%，mRNA肿瘤疫苗五年数据印证疗效

Core Insights - Moderna (MRNA.US) shares rose 5.6% in pre-market trading, reaching $52.6, following a significant increase of nearly 16% the previous day [1] - Merck and Moderna jointly disclosed phase II clinical trial data for the mRNA cancer vaccine mRNA-4157 in combination with Keytruda, showing a 49% reduction in the risk of recurrence or death for high-risk stage III/IV melanoma patients compared to Keytruda monotherapy [1] - The data supports the scientific hypothesis that mRNA cancer vaccines can induce a durable immune response [1]